[Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer].

Abstract

OBJECTIVE:

To evaluate the effect and adverse reaction of China made topotecan in the treatment of small-cell lung cancer (ACLC) and recurrent ovarian cancer (OV).

METHODS:

From January to July, 2000, topotecan was used to treat 141 patients at a dose of 1.2 mg/m2, given daily as 30-min i.v. infusion for 5 days. Treatment was repeated once every 3 weeks. Of the 141 patients, 118 were evaluable for therapeutic efficacy. All the patients received a total of 286 cycles of treatment were assessable for analysis of adverse reactions.

RESULTS:

Among the evaluable patients, there were 5 CR, 35 PR, with an overall response rate (RR) of 33.8%. There were 3 CR and 26 PR in 89 patients with SCLC (RR 32.5%). The response rate of patients with or without prior chemotherapy was 15.6% and 50%, respectively. In 29 patients with recurrent OV, there were 2 CR and 9 PR (RR 37.9%). The major toxic effect was myelosuppression. Non-hematopoietic toxicities were mild and tolerable.

CONCLUSION:

Topotecan is an effective drug for the treatment of SCLC and recurrent OV. It is still efficacious in some patients who previously received standard chemotherapy. The major dose-limiting toxicity is myelosuppression. The response rate and toxicity of the domestically made topotecan are comparable with those of the imported one.

• Authors: F Feng, X He, Y Shi
• Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] (Zhonghua Zhong Liu Za Zhi) Vol. 23 Issue 2 Pg. 155-8 (Mar 2001) ISSN: 0253-3766 [Print] China
• PMID: 11783024 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Topotecan

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Carcinoma, Small Cell (drug therapy, pathology)
• Female
• Humans
• Leukopoiesis (drug effects)
• Lung Neoplasms (drug therapy, pathology)
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Ovarian Neoplasms (drug therapy, pathology)
• Topotecan (adverse effects, therapeutic use)
• Treatment Outcome